Prostate-specific membrane antigen as a target for cancer imaging and therapy.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  The Quarterly Journal of Nuclear Medicine and Molecular Imaging

• Publication date

  2015-07-24

• Fields of study

  Medicine

• Identifiers
  PMID 26213140PMCID PMC4859214
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.

  2016cited by this paper
• Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors

  2015cited by this paper
• Synthesis and preclinical validation of [F-18]P238 as a PET imaging agent for prostate specific membrane antigen (PSMA)

  2015cited by this paper
• Synthesis and evaluation of constrained phosphoramidate inhibitors of prostate-specific membrane antigen.

  2015cited by this paper
• Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer

  2015cited by this paper
• 18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer

  2015cited by this paper
• Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy

  2015cited by this paper
• Synthesis and Evaluation of Gd(III) -Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate-Specific Membrane Antigen.

  2015cited by this paper
• 68Ga-PSMA ligand PET versus 18F-NaF PET: evaluation of response to 223Ra therapy in a prostate cancer patient

  2015cited by this paper
• Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer

  2015cited by this paper
• Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen

  2015cited by this paper
• FDG PET/CT imaging as a biomarker in lymphoma

  2015cited by this paper
• Value of functional imaging by PET in esophageal cancer.

  2015cited by this paper
• Radiofluorination of PSMA-HBED via Al18F2+ Chelation and Biological Evaluations In Vitro

  2015cited by this paper
• 68Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer

  2015cited by this paper
• PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer.

  2015cited by this paper
• Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

  2015cited by this paper
• BAY 1075553 PET-CT for Staging and Restaging Prostate Cancer Patients: Comparison with [18F] Fluorocholine PET-CT (Phase I Study)

  2015cited by this paper
• Lung cancer.

  2015cited by this paper
• Detection of brain metastasis with 68Ga-labeled PSMA ligand PET/CT: a novel radiotracer for imaging of prostate carcinoma.

  2015cited by this paper
• Photoimmunotherapy Targeting Prostate-Specific Membrane Antigen: Are Antibody Fragments as Effective as Antibodies?

  2015cited by this paper
• Evaluation of a PSMA-targeted BNF nanoparticle construct.

  2015cited by this paper
• Supplementary Table 1

  2015cited by this paper
• Expression of Prostate-Specific Membrane Antigen in Lung Cancer Cells and Tumor Neovasculature Endothelial Cells and Its Clinical Significance

  2015cited by this paper
• Design of highly potent urea-based, exosite-binding inhibitors selective for glutamate carboxypeptidase II.

  2015cited by this paper
• 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies

  2015cited by this paper
• In Vivo Molecular MRI Imaging of Prostate Cancer by Targeting PSMA with Polypeptide-Labeled Superparamagnetic Iron Oxide Nanoparticles

  2015cited by this paper
• Preclinical Evaluation of 86Y-Labeled Inhibitors of Prostate-Specific Membrane Antigen for Dosimetry Estimates

  2015cited by this paper
• A shortcut to high-affinity Ga-68 and Cu-64 radiopharmaceuticals: one-pot click chemistry trimerisation on the TRAP platform.

  2015cited by this paper
• Preparation and evaluation of carborane-derived inhibitors of prostate specific membrane antigen (PSMA).

  2014cited by this paper
• Development of Targeted Near-Infrared Imaging Agents for Prostate Cancer

  2014cited by this paper
• Preclinical evaluation of a bispecific low‐molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer

  2014cited by this paper
• Heterobivalent Agents Targeting PSMA and Integrin-αvβ3

  2014cited by this paper
• Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases

  2014cited by this paper
• Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer

  2014cited by this paper
• Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep

  2014cited by this paper
• Prostate‐specific membrane antigen expression in tumor‐associated vasculature of breast cancers

  2014cited by this paper
• A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy.

  2014cited by this paper
• Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer

  2014cited by this paper
• 64Cu-Labeled Inhibitors of Prostate-Specific Membrane Antigen for PET Imaging of Prostate Cancer

  2014cited by this paper
• 68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma

  2014cited by this paper
• Improving the biodistribution of PSMA‐targeting tracers with a highly negatively charged linker

  2014cited by this paper
• 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer

  2014cited by this paper
• Pharmacokinetic and Biodistribution Assessment of a Near Infrared-Labeled PSMA-Specific Small Molecule in Tumor-Bearing Mice

  2014cited by this paper
• Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.

  2014cited by this paper
• Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery.

  2014cited by this paper
• Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.

  2014cited by this paper
• 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer

  2014cited by this paper
• Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy

  2014cited by this paper
• Fluorescence-guided surgery with live molecular navigation — a new cutting edge

  2013cited by this paper
• Development of tumor-targeted near infrared probes for fluorescence guided surgery.

  2013cited by this paper
• Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer

  2013cited by this paper
• PSMA as a target for radiolabelled small molecules

  2013cited by this paper
• Comment on Afshar-Oromieh et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions

  2013cited by this paper
• Cellular distribution and heterogeneity of Psa and Psma expression in normal, hyperplasia and human prostate cancer.

  2013cited by this paper
• Synthesis and SAR of ⁹⁹mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates.

  2013cited by this paper
• Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer.

  2013cited by this paper
• Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).

  2013cited by this paper
• PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer

  2013cited by this paper
• Preclinical evaluation of BAY 1075553, a novel 18F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer

  2013cited by this paper
• Image-guided cancer surgery using near-infrared fluorescence

  2013cited by this paper
• 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer

  2013cited by this paper
• First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer

  2013cited by this paper
• Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography.

  2013cited by this paper
• PSMA‐targeted SPECT agents: Mode of binding effect on in vitro performance

  2013cited by this paper
• Radiosynthesis of [18F]FEt-Tyr-urea-Glu ([18F]FEtTUG) as a new PSMA ligand

  2013cited by this paper
• Preparation of asymmetric urea derivatives that target prostate-specific membrane antigen for SPECT imaging.

  2013cited by this paper
• A multivalent approach of imaging probe design to overcome an endogenous anion binding competition for noninvasive assessment of prostate specific membrane antigen.

  2013cited by this paper
• Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

  2012cited by this paper
• Glutamate carboxypeptidase II: an overview of structural studies and their importance for structure-based drug design and deciphering the reaction mechanism of the enzyme.

  2012cited by this paper
• Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer

  2012cited by this paper
• Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner

  2012cited by this paper
• Prostate-specific membrane antigen: a new potential prognostic marker of osteosarcoma

  2012cited by this paper
• 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.

  2012cited by this paper
• Small molecule inhibitors of PSMA incorporating technetium-99m for imaging prostate cancer: Effects of chelate design on pharmacokinetics

  2012cited by this paper
• One pot radiofluorination of a new potential PSMA ligand [Al18F]NOTA‐DUPA‐Pep

  2012cited by this paper
• Radiofluorinated derivatives of 2-(phosphonomethyl)pentanedioic acid as inhibitors of prostate specific membrane antigen (PSMA) for the imaging of prostate cancer.

  2012cited by this paper
• High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity

  2012cited by this paper
• Triazole Appending Agent (TAAG): A New Synthon for Preparing Iodine-Based Molecular Imaging and Radiotherapy Agents.

  2012cited by this paper
• PSMA-targeted theranostic nanoplex for prostate cancer therapy.

  2012cited by this paper
• A phosphoramidate‐based prostate‐specific membrane antigen‐targeted SPECT agent

  2012cited by this paper
• Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen.

  2012cited by this paper
• Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

  2012cited by this paper
• Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer.

  2011cited by this paper
• Radiosynthesis of a new PSMA targeting ligand ([18F]FPy-DUPA-Pep).

  2011cited by this paper
• In Vitro and In Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen

  2011cited by this paper
• 2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer

  2011cited by this paper
• Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles.

  2011cited by this paper
• A modular system for the synthesis of multiplexed magnetic resonance probes.

  2011cited by this paper
• A Modular Strategy to Prepare Multivalent Inhibitors of Prostate-Specific Membrane Antigen (PSMA)

  2011cited by this paper
• Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen.

  2011cited by this paper
• Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers.

  2011cited by this paper
• Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme.

  2011cited by this paper
• Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancer

  2010cited by this paper
• Expression of prostate‐specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non‐polyglutamated folate, folic acid

  2010cited by this paper
• Phase I trial of fractionated-dose 177lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC).

  2010cited by this paper
• 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer.

  2010cited by this paper
• A targeted low molecular weight near-infrared fluorescent probe for prostate cancer.

  2010cited by this paper
• Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies.

  2010cited by this paper
• A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules.

  2010cited by this paper

• Comparación de imágenes de 99mTc-HYNIC-PSMA-11, gammagrafía ósea e investigación posterior a la terapia con radioligandos en los pacientes con CPRCm: experiencia de un solo centro

  2025cites this paper
• Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Brain Metastasis of Various Tumors Using Positron Emission Tomography?

  2025cites this paper
• Biodistribution and Semiquantitative Analysis of 99mTc-HYNIC-PSMA-11in Prostate Cancer Patients: A Retrospective Study

  2025cites this paper
• PSMA-targeted Small Molecule-Drug Conjugates based on a Post-Prolyl Peptidase Cleavable Linker for the Treatment of Prostate Cancer.

  2025cites this paper
• Beyond the Pill: How Nanorobots are Transforming Drug Delivery

  2025cites this paper
• Comparison of Prostate-specific Membrane Antigen Reporting and Data System Version 1.0 versus 2.0 for Prostate Cancer Assessment.

  2025cites this paper
• Introduction of prostate-specific membrane antigen adjusted Prostate Imaging Reporting and Data System: A new approach to enhancing the accuracy of diagnosing naïve-primary prostate cancer

  2025cites this paper
• Packing the Punch: Current and Emerging Treatment Strategies in Metastatic Castration-Sensitive Prostate Cancer

  2025cites this paper
• Comparison of 99mTc-HYNIC-PSMA-11, bone scan and post radioligand therapy images in mCRPC patients: A single center experience.

  2025cites this paper
• Discovery of Glutamate Carboxypeptidase III Ligands to Compete the Uptake of [177Lu]Lu-PSMA-617 in Healthy Organs.

  2024cites this paper
• Synthesis and Preclinical Evaluation of Urea-Based Prostate-Specific Membrane Antigen-Targeted Conjugates Labeled with 177Lu.

  2024cites this paper
• Targeted interleukin-2 enhances the in vivo anti-cancer activity of Pluvicto™

  2024cites this paper
• Targeted Therapy for Prostate Cancer by Prostate-Specific Membrane Antigen-Targeted Small-Molecule Drug Conjugates.

  2024cites this paper
• Exploring the impact of PEGylation on pharmacokinetics: a size-dependent effect of polyethylene glycol on prostate-specific membrane antigen inhibitors

  2024cites this paper
• The development of 177Lu-DOTA-CC-PSMA following a unified “Click Chemistry” protocol of synthesizing metal nuclide-conjugated radiopharmaceuticals

  2024cites this paper
• Cyclohexanediamine Triazole (CHDT) Functionalization Enables Labeling of Target Molecules with Al18F/68Ga/111In

  2024cites this paper
• Flourine-18 Prostate-Specific Membrane Antigen-1007 Positron Emission Tomography Imaging in Staging of Primary and Secondary Prostate Cancer—A Retrospective Observational Cohort Study

  2024cites this paper
• The quantitative impact of prostate-specific membrane antigen (PSMA) PET/CT staging in newly diagnosed metastatic prostate cancer and treatment-decision implications

  2024cites this paper
• Design, preclinical evaluation, and first-in-human PET study of [68Ga]Ga-PSFA-01: a PSMA/FAP heterobivalent tracer

  2024cites this paper
• Prostate-Specific Membrane Antigen Use in Glioma Management

  2024cites this paper
• Assessing Krenning’s score on 68Ga-DOTATATE PET-CT and miPSMA score on 68Ga-PSMA-11 PET-CT in TENIS: a comparison with FDG PET/CT and examining the feasibility of targeted radionuclide therapy

  2024cites this paper
• Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug Conjugates for Treatment of Prostate Cancer: Preclinical Evaluation

  2024cites this paper
• Imageological/Structural Study regarding the Improved Pharmacokinetics by 68Ga-Labeled PEGylated PSMA Multimer in Prostate Cancer

  2023cites this paper
• Technetium(I) carbonyl complexes for nuclear medicine: Coordination-chemical aspect

  2023cites this paper
• The role of NFATc1 in the progression and metastasis of prostate cancer: A review on the molecular mechanisms and signaling pathways

  2023cites this paper
• Molecular MR Imaging of Prostate Cancer by Specified Iron Oxide Nanoparticles With PSMA‐11 Peptides: A Preclinical Study

  2023cites this paper
• Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer.

  2023cites this paper
• Targeting prostate cancer with docetaxel-loaded peptide 563-conjugated PEtOx-co-PEI_30%-b-PCL polymeric micelle nanocarriers

  2023cites this paper
• Nanoparticle-Based Radioconjugates for Targeted Imaging and Therapy of Prostate Cancer

  2023cites this paper
• Halogen Replacement on the Lysine Side Chain of Lys-Urea-Glu-Based PSMA Inhibitors Leads to Significant Changes in Targeting Properties

  2023cites this paper
• Metamorphosis of prostate specific membrane antigen (PSMA) inhibitors

  2022cites this paper
• Role of PET/Computed Tomography in Elderly Thyroid Cancer: Tumor Biology and Clinical Management.

  2022cites this paper
• Ga-68 Prostate-Specific Membrane Antigen PET/CT: Imaging and Clinical Perspective in Prostate Cancer: Imaging and Clinical Perspective in Prostate Cancer.

  2022cites this paper
• Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics

  2022cites this paper
• PSA-Stratified Performance of [18F]DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer Patients under Androgen Deprivation Therapy

  2022cites this paper
• PSMA-targeted NIR probes for image-guided detection of prostate cancer.

  2022cites this paper
• The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer—A Practical Clinical Review

  2022cites this paper
• Basics of Physics and Radiobiology for Radiopharmaceutical Therapies.

  2022cites this paper
• Specified iron oxide nanoparticles by PSMA-11 as a promising nanomolecular imaging probe for early detection of prostate cancer

  2022cites this paper
• Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands

  2022cites this paper
• Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends

  2022cites this paper
• Preclinical development of a novel [68Ga]Ga-/[177Lu]Lu-labeled agent for PSMA-targeted imaging and therapy

  2022cites this paper
• Towards a Precision Medicine Approach and In Situ Vaccination against Prostate Cancer by PSMA-Retargeted oHSV

  2021cites this paper
• A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand

  2021cites this paper
• Molecular imaging in oncology: Current impact and future directions

  2021cites this paper
• PET/CT Variants and Pitfalls in Liver, Biliary Tract, Gallbladder and Pancreas.

  2021cites this paper
• Radioresistance in Prostate Cancer: Focus on the Interplay between NF-κB and SOD

  2021cites this paper
• Prostate Cancer Theranostics

  2021cites this paper
• Developing μSpherePlatform Using a Commercial Hairbrush: An Agarose 3D Culture Platform for Deep-Tissue Imaging of Prostate Cancer.

  2021cites this paper
• Comparing 99mTc-PSMA to 99mTc-MDP in Prostate Cancer Staging of the Skeletal System

  2021cites this paper
• Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer

  2021cites this paper
• Protocol for 18F-PSMA PET imaging in staging and management of prostate cancer - a retrospective cohort study

  2021cites this paper
• Synthesis and evaluation of tumor-homing peptides for targeting prostate cancer

  2021cites this paper
• Prostate-Specific Membrane Antigen Expression in Patients With Differentiated Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET/CT

  2021cites this paper
• PET/CT using 68Ga‐PSMA‐617 versus 18F‐fluorodeoxyglucose to differentiate low‐ and high‐grade gliomas

  2021cites this paper
• Evaluation of Radiation dosimetry of 99mTc-HYNIC-PSMA and imaging in prostate cancer

  2020cites this paper
• Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov

  2020cites this paper
• Toward 18F‐Labeled Theranostics: A Single Agent that Can Be Labeled with 18F, 64Cu, or 177Lu

  2020cites this paper
• 99MTc-PSMA – radionuclide imaging of prostate cancer: an innovative diagnostic direction in nuclear medicine

  2020cites this paper
• A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile

  2020cites this paper
• Preclinical Evaluation of 213Bi- and 225Ac-Labeled Low-Molecular-Weight Compounds for Radiopharmaceutical Therapy of Prostate Cancer

  2020cites this paper
• A simple strategy to reduce the salivary gland and kidney uptake of PSMA targeting small molecule radiopharmaceuticals

  2020cites this paper
• Nanoparticles for Targeting of Prostate Cancer.

  2020cites this paper
• Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer—Optimization of the Affinity towards PSMA by Linker Modification in Murine Model

  2020influential citation
• Prostate‐specific antigen modulates the osteogenic differentiation of MSCs via the cadherin 11‐Akt axis

  2020cites this paper
• Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients

  2020cites this paper
• Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications

  2020influential citation
• PET Imaging Quantifying 68Ga-PSMA-11 Uptake in Metastatic Colorectal Cancer

  2020cites this paper
• Modular Medical Imaging Agents Based on Azide–Alkyne Huisgen Cycloadditions: Synthesis and Pre‐Clinical Evaluation of 18F‐Labeled PSMA‐Tracers for Prostate Cancer Imaging

  2020cites this paper
• Prostate-specific membrane antigen (PSMA) imaging: the past is prologue and the future is scintillating

  2020cites this paper
• Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer

  2019cites this paper
• Overexpression of prostate specific membrane antigen by canine hemangiosarcoma cells provides opportunity for the molecular detection of disease burdens within hemorrhagic body cavity effusions

  2019cites this paper
• Current Trends in Cancer Nanotheranostics: Metallic, Polymeric, and Lipid-Based Systems

  2019cites this paper
• Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications.

  2019cites this paper
• Integrating Small Animal Irradiators with Functional Imaging for Advanced Preclinical Radiotherapy Research

  2019cites this paper
• One-Step 18F-Labeling and Preclinical Evaluation of Prostate-Specific Membrane Antigen Trifluoroborate Probes for Cancer Imaging

  2019cites this paper
• Surface Modification of Liposomes by a Lipopolymer Targeting Prostate Specific Membrane Antigen for Theranostic Delivery in Prostate Cancer

  2019cites this paper
• Differential Uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in Low-Grade Versus High-Grade Gliomas in Treatment-Naive Patients

  2019cites this paper
• Comparison of prostate‐specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer

  2019cites this paper
• Uptake of prostate-specific membrane antigen-targeted 18F-DCFPyL in avascular necrosis of the femoral head

  2019cites this paper
• PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy.

  2019cites this paper
• Modular Synthesis of DOTA-Metal based PSMA Targeted Imaging Agents for MRI and PET of Prostate Cancer.

  2019cites this paper
• 177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy

  2019cites this paper
• PEG-coated and Gd-loaded fluorescent silica nanoparticles for targeted prostate cancer magnetic resonance imaging and fluorescence imaging

  2019cites this paper
• Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer

  2019cites this paper
• N-Heterocyclic Carbene Platinum Complexes: A Big Step Forward for Effective Antitumor Compounds

  2019cites this paper
• TEP-PSMA

  2019cites this paper
• Radium and other alpha emitters in prostate cancer

  2018cites this paper
• Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT

  2018cites this paper
• Structure-activity relationships of succinimidyl-Cys-C(O)-Glu derivatives with different near-infrared fluorophores as optical imaging probes for prostate-specific membrane antigen.

  2018cites this paper
• Radiopharmaceuticals for Bone Metastases

  2018cites this paper
• Radiotheranostics in Cancer Diagnosis and Management.

  2018cites this paper
• Salicylic Acid-Based Polymeric Contrast Agents for Molecular Magnetic Resonance Imaging of Prostate Cancer.

  2018cites this paper
• Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid Tumors.

  2018cites this paper
• Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody

  2018cites this paper
• Evaluation of 111In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen

  2018cites this paper
• Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Near-Infrared Imaging Agent for Fluorescence-Guided Surgery of Prostate Cancer

  2018cites this paper
• Novel gadopentetic acid-doped silica nanoparticles conjugated with YPSMA-1 targeting prostate cancer for MR imaging: an in vitro study.

  2018cites this paper
• Integration of PSMA-targeted PET imaging into the armamentarium for detecting clinically significant prostate cancer

  2018cites this paper
• Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer

  2018cites this paper